A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ERNA SEC filings page.
This page shows Ernexa Therapeutics Inc. (ERNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Ernexa's reported economics are dominated by development spending and financing, not by product revenue or internally funded operations.
Operating cash outflow narrowed from$15.8M in FY2024 to$7.0M in FY2025 as SG&A fell60.7% and R&D fell9.7% ; however, the FY2025 net loss of$14.1M still exceeded cash outflow, showing that reduced spending—not operating revenue—drove the cash improvement.
The balance sheet became less burdened by liabilities in FY2025: liabilities fell
FY2025 financing provided
Financial Health Signals
We do not publish a peer-relative financial health score for Ernexa Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Ernexa Therapeutics Inc. passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass.
Ernexa Therapeutics Inc. reported a net loss of $14.1M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Ernexa Therapeutics Inc. reported an operating loss of $9.3M against $22K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Ernexa Therapeutics Inc.'s EBITDA was -$3.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Ernexa Therapeutics Inc. reported a net loss of $2.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Ernexa Therapeutics Inc. earned -$1.89 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Ernexa Therapeutics Inc. recorded an outflow of $3.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Ernexa Therapeutics Inc. held $5.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Ernexa Therapeutics Inc.'s quarterly ROE was -67.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 32.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 57.7 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Ernexa Therapeutics Inc. invested $1.9M in research and development in Q3 2026. This represents an increase of 80.8% from the same quarter a year earlier. Against the prior quarter it is down 33.0%.
Ernexa Therapeutics Inc. reported no capital expenditure in Q3 2026. Against the prior quarter it is down 100.0%.
Not reported for Q3 2026.
ERNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1K |
| Cost of Revenue | $0n/m | $0n/m | N/A | N/A | $0n/m | $0-100.0% | N/A | $0 |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1K |
| R&D Expenses | $1.9M+80.8% | $2.8M+145.8% | $1.9M+46.3% | $676K-41.6% | $1.0M+3.4% | $1.1M+15.1% | $1.3M-10.2% | $1.2M-14.9% |
| SG&A Expenses | $1.1M+16.8% | $1.3M-3.9% | $1.6M+14.8% | $1.4M-7.9% | $958K-71.7% | $1.4M-65.0% | $1.4M-67.1% | $1.5M-64.6% |
| Operating Income | -$3.0Mn/m | -$4.1Mn/m | -$5.6Mn/m | -$2.1Mn/m | -$2.0Mn/m | -$2.5Mn/m | -$2.7Mn/m | -$2.7Mn/m |
| EBITDA | -$3.0Mn/m | -$4.1Mn/m | -$5.6Mn/m | -$2.1Mn/m | -$2.0Mn/m | -$2.5Mn/m | -$2.7Mn/m | -$2.7Mn/m |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $6K-98.5% | -$2.7M |
| Income Tax | N/A | N/A | -$40K-600.0% | -$62K-663.6% | $6K-50.0% | $3K0.0% | $8K+100.0% | $11Kn/m |
| Net Income | -$2.9Mn/m | -$4.0Mn/m | -$5.5Mn/m | -$1.5M | -$1.2Mn/m | -$3.1Mn/m | -$8.2Mn/m | N/A |
| EPS (Basic) | -$1.89 | -$3.40 | -$6.95 | N/A | -$3.77 | -$15.19 | -$57.76 | N/A |
| EPS (Diluted) | -$1.89 | -$3.40 | -$6.95 | N/A | -$3.77 | -$15.19 | -$57.76 | N/A |
| Diluted Shares (Avg) | 2M | 1M | 792,000 | N/A | 329,000 | 207,000 | 142,000 | N/A |
ERNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.1M+15.1% | $6.3M-16.7% | $10.5M+108.4% | $5.8M+10.7% | $6.2M-20.0% | $7.6M-83.7% | $5.1M-89.8% | $5.3M-89.3% |
| Current Assets | $6.7M+99.1% | $5.9M+23.0% | $10.0M+352.1% | $3.1M+33.2% | $3.4M-28.6% | $4.8M+33.7% | $2.2M-64.1% | $2.4M-75.5% |
| Cash & Equivalents | $5.6M+83.0% | $5.0M+16.5% | $9.2M+378.5% | $1.9M+9.0% | $3.0M-28.5% | $4.3M+66.9% | $1.9M-62.5% | $1.7M-77.2% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | N/A | N/A | N/A | $2.0M0.0% | $2.0M0.0% | $2.0M0.0% | $2.0M0.0% | $2.0M0.0% |
| Total Liabilities | $2.8M+5.8% | $3.1M-0.8% | $3.7M-66.5% | $3.4M-3.8% | $2.6M-95.1% | $3.1M-94.3% | $11.0M-79.3% | $3.6M-92.4% |
| Current Liabilities | $2.6M+21.9% | $2.9M+10.6% | $3.5M-66.9% | $3.1M+6.0% | $2.1M-78.5% | $2.7M-72.4% | $10.4M+34.4% | $2.9M-55.3% |
| Non-Current Liabilities | $139K-69.7% | $183K-62.6% | $227K-60.2% | $320K-49.2% | $458K-98.9% | $489K-98.9% | $571K-98.7% | $630K-98.4% |
| Total Equity | $4.4M+21.9% | $3.2M-28.0% | $6.9Mn/m | $2.4M+41.2% | $3.6Mn/m | $4.4Mn/m | -$6.0Mn/m | $1.7M-23.8% |
| Retained Earnings | -$258.1Mn/m | -$255.2Mn/m | -$251.1Mn/m | -$245.6Mn/m | -$244.1Mn/m | -$242.9Mn/m | -$239.7Mn/m | -$231.5Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
ERNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2Mn/m | -$4.2Mn/m | -$2.3Mn/m | -$1.1Mn/m | -$1.3Mn/m | -$2.5Mn/m | -$2.1Mn/m | -$3.5Mn/m |
| Depreciation & Amortization | $10K-41.2% | $9K-47.1% | $8K-55.6% | $13K-31.6% | $17K-54.1% | $17K-61.4% | $18K-53.8% | $19K-13.6% |
| Stock-Based Compensation | $377K+28.7% | $320K-13.0% | $309K-38.4% | N/A | $293K-27.7% | $368K-13.0% | $502K+78.0% | N/A |
| Capital Expenditures | $0 | $3K | $2K | $15Kn/m | N/A | N/A | N/A | $0-100.0% |
| Free Cash Flow | -$3.2M | -$4.2M | -$2.3M | -$1.2Mn/m | N/A | N/A | N/A | -$3.5Mn/m |
| Investing Cash Flow | $0 | -$3K | -$2K | -$15Kn/m | N/A | N/A | N/A | $0n/m |
| Financing Cash Flow | $3.7M+14196.2% | $6K-99.9% | $9.6M+324.1% | $0-100.0% | $26K-99.3% | $4.9Mn/m | $2.3M+62.7% | $1.0M-86.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ERNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 100.0% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -269700.0% |
| Return on Equity | -67.6%-32.9pp | -125.3%-54.6pp | -80.3% | -62.6% | -34.7% | -70.7% | N/A | N/A |
| Return on Assets | -41.4%-21.3pp | -63.5%-22.1pp | -52.2%+109.9pp | -25.8% | -20.1%+324.6pp | -41.4%-29.5pp | -162.1%-148.7pp | N/A |
| Current Ratio | 2.57+1.0x | 2.01+0.2x | 2.89+2.7x | 1.01+0.2x | 1.58+1.1x | 1.81+1.4x | 0.21-0.6x | 0.80-0.7x |
| Liabilities-to-Equity | 0.63-0.1x | 0.97+0.3x | 0.54 | 1.43-0.7x | 0.73 | 0.71 | N/A | 2.10-18.9x |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -354500.0% |
Not reported in any period shown, so not listed: Net Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. ERNA | FY2025 | N/A | -$14.1M | N/A | $2.7M | — |
| Mustang Bio, Inc. MBIO | FY2025 | N/A | -$1.9M | N/A | $2.9M | — |
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $5.8M | 43/100 |
| Purple Biotech Ltd. PPBT | FY2025 | N/A | N/A | N/A | $2.8M | — |
| Calidi Biotherapeutics, Inc. CLDI | FY2025 | N/A | -$19.9M | N/A | $1.8M | — |
| NeuroSense Therapeutics Ltd. NRSN | FY2025 | N/A | N/A | N/A | $2.6M | — |
Where Ernexa Therapeutics Inc. Ranks
Frequently Asked Questions
No, Ernexa Therapeutics Inc. (ERNA) reported a net loss of $14.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $14.1M.
Ernexa Therapeutics Inc. (ERNA) had EBITDA of -$9.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Ernexa Therapeutics Inc. (ERNA) has a return on equity of -586.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Ernexa Therapeutics Inc. (ERNA) recorded an outflow of $7.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Ernexa Therapeutics Inc. (ERNA) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Ernexa Therapeutics Inc. (ERNA) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.
Ernexa Therapeutics Inc. (ERNA) invested $37K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Ernexa Therapeutics Inc. (ERNA) invested $4.2M in research and development during fiscal year 2025.
Ernexa Therapeutics Inc. (ERNA) had a current ratio of 1.01 as of fiscal year 2025, which is considered adequate.
Ernexa Therapeutics Inc. (ERNA) had a liabilities-to-equity ratio of 1.43 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Ernexa Therapeutics Inc. (ERNA) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Ernexa Therapeutics Inc. (ERNA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $2.7M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Ernexa Therapeutics Inc. (ERNA) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $2.7M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Ernexa Therapeutics Inc. (ERNA) held $1.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Ernexa Therapeutics Inc. (ERNA) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Ernexa Therapeutics Inc. (ERNA) reported a net loss of $14.1M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Ernexa Therapeutics Inc. (ERNA) reported an operating loss of $9.3M against $22K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.